BD MediGlycopyrronium Bromide + Formoterol Fumarate
Brands & Prices (2)
📋 Indications & Uses Dosage & Administration⚠️ Contraindications⚡ Side Effects & Adverse Reactions🛡️ Warnings & Precautions🔬 Pharmacology & Mechanism
Brand Formulations & Prices
2 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesBeviprex is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Dosage & AdministrationAdults
: Should be administered as 2 puffs twice daily, in the morning and in the evening.
Use in patients with severe renal impairment should be considered if the potential benefit of the treatment outweighs the risk.
All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication. This preparation is also contraindicated in patients with hypersensitivity to glycopyrronium bromide, formoterol fumarate or to any component of the product.
The most common adverse reactions include cough and urinary tract infection. Possible side effects are sudden breathing problems, headache, tremor, nervousness, rash, swelling of the face, mouth and tongue, hives, increase blood pressure, chest pain, irregular heartbeat, muscle spasm, muscle weakness, eye pain or discomfort and urinary retention.
Beviprex should not be used with an additional medicine containing a LABA because of risk of overdose.
Not indicated for the relief of acute bronchospasm
Do not initiate in acutely deteriorating COPD or to treat acute symptoms
If paradoxical bronchospasm occurs, discontinue Beviprex and institute alternative therapy
Use with caution in patients with cardiovascular disorders
Use with patients with convulsive disorders, thyrotoxicosis, diabetes mellitus and ketoacidosis.
Be alert to hypokalemia and hyperglycemia
Worsening of narrow angle glaucoma may occur. Use with caution with patients with narrow-angle glaucoma
Worsening of urinary retention may occur. Use with caution with patients with prostatic hyperplasia or bladder-neck obstruction
This preparation contains two bronchodilators: Glycopyrronium is a long-acting muscarinic antagonist (LAMA) and Formoterol is a long-acting β2-adrenergic agonist (LABA) with a rapid onset of action. Glycopyrronium has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of the M3 receptor at the smooth muscle leading to bronchodilation. Formoterol causes direct relaxation of airway smooth muscle as a consequence of the increase in cyclic AMP through activation of adenylyl cyclase.